EirGenix Report Results of EG12014 (biosimilar- trastuzumab) in P-III Trial for HER2-Positive Breast Cancer
Shots:
- The P-III trial involves assessing the safety- immunogenicity and PK of EG12014 (trastuzumab- biosimilar) vs Herceptin in 807 patients in a ratio (1:1) for HER2-positive breast cancer
- The trial met its 1EPs showed equivalent efficacy to Herceptin in regards to clinical response (pCR) in both analysis populations (per-protocol and full-analysis sets) and demonstrated a comparable safety profile in the pre-operative treatment setting
- The company is preparing to submit BLA to the US FDA- MAA to EMA and NDA to TFDA
Ref: PRNewswire | Image: Novatek International
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com